Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Feb
20
Today In Oncology
Stage II Melanoma Adjuvant Pembrolizumab and Risk of New Skin Cancers
Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo